Delayed
Toronto S.E.
12:50:51 30/04/2024 am IST
|
5-day change
|
1st Jan Change
|
0.02
CAD
|
-20.00%
|
|
0.00%
|
-20.00%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
61.57
|
52.04
|
30.6
|
8.95
|
5.304
|
7.232
|
-
|
Enterprise Value (EV)
1 |
61.57
|
52.04
|
30.6
|
8.95
|
5.304
|
7.232
|
7.232
|
P/E ratio
|
-
|
-7.29
x
|
-
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.94
x
|
1
x
|
0.49
x
|
0.14
x
|
0.07
x
|
0.1
x
|
0.08
x
|
EV / Revenue
|
1.94
x
|
1
x
|
0.49
x
|
0.14
x
|
0.07
x
|
0.1
x
|
0.08
x
|
EV / EBITDA
|
-17.2
x
|
13.7
x
|
15.2
x
|
-1.71
x
|
1.57
x
|
-4.02
x
|
2.26
x
|
EV / FCF
|
-23,53,400
x
|
-1,20,15,994
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
87,963
|
1,02,039
|
1,05,515
|
1,49,166
|
2,12,167
|
2,89,273
|
-
|
Reference price
2 |
0.7000
|
0.5100
|
0.2900
|
0.0600
|
0.0250
|
0.0250
|
0.0250
|
Announcement Date
|
19/03/20
|
31/03/21
|
31/03/22
|
01/04/23
|
01/04/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
31.77
|
52.05
|
62.29
|
63.23
|
71.07
|
75.8
|
86.6
|
EBITDA
1 |
-3.584
|
3.8
|
2.011
|
-5.248
|
3.377
|
-1.8
|
3.2
|
EBIT
|
-2.2
|
-2.768
|
-7.639
|
-
|
-
|
-
|
-
|
Operating Margin
|
-6.92%
|
-5.32%
|
-12.26%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-6.418
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-12.33%
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-0.0700
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-26.16
|
-4.331
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-82.36%
|
-8.32%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
31/03/21
|
31/03/22
|
01/04/23
|
01/04/24
|
-
|
-
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
12.48
|
17.5
|
15.69
|
17.56
|
16.9
|
18.25
|
18.44
|
EBITDA
1 |
-
|
-0.391
|
-1.683
|
-1.48
|
-0.4756
|
1.362
|
1.031
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/05/22
|
15/08/22
|
15/11/22
|
01/04/23
|
15/05/23
|
14/08/23
|
14/11/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-26.2
|
-4.33
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
14
|
5.84
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
44.18%
|
11.22%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
31/03/21
|
31/03/22
|
01/04/23
|
01/04/24
|
-
|
-
|
Last Close Price
0.025
CAD Average target price
0.06
CAD Spread / Average Target +140.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.00% | 5.28M | | +25.97% | 661B | | +26.74% | 566B | | -6.59% | 352B | | +18.70% | 332B | | +3.62% | 283B | | +13.43% | 231B | | +4.71% | 200B | | -9.53% | 195B | | -4.30% | 145B |
Other Pharmaceuticals
|